A New Era in PROTAC Drug Development: Potential Alone Is No Longer Sufficient

Proteolysis targeting chimeras (PROTACs) have recently moved beyond being a scientific novelty and are transitioning into a clinical treatment modality. The mere power of these drug candidates to degrade disease-causing proteins is no longer accepted as a sufficient justification for them to become viable drugs. In the later stages of the development process, disadvantages such as insufficient drug residence time in the body, safety issues, off-target tissue effects, and manufacturing challenges can emerge. Therefore, to develop a successful drug, chemistry, pharmacology, safety, and clinical strategy must be evaluated together from the very beginning of the process. Being a potent degrader in a laboratory setting does not mean that the molecule is a successful drug candidate.

PROTACs are recognized as a significant technology that redraws the boundaries of the drug discovery world and goes beyond traditional methods. Rather than merely halting the activity of disease-related proteins, they rely on a mechanism that completely eliminates them from the cell by utilizing the ubiquitin-proteasome system. This feature has made it possible to treat even proteins that were previously considered 'undruggable' and could not be inhibited by traditional methods. Over the past few years, excitement in the scientific community has largely focused on proving this unique mechanism. However, at the point reached today, with clinical programs advancing, the fundamental question is no longer whether this mechanism works.

The real topic of debate today is whether these promising molecules in the laboratory can be transformed into clinically viable and commercially valuable drugs. As clinical research progresses and this technology approaches regulatory approval stages, expectations have changed significantly. It is no longer enough to merely show that the target protein is successfully degraded. Developers must prove that the drug has an appropriate exposure profile, an adequate safety margin, a correct formulation strategy, and a viable manufacturing roadmap. At this stage, unless scientific innovativeness is combined with technical feasibility, it cannot carry the project to success.

Because PROTAC molecules have a much more complex mechanism than traditional small-molecule drugs, focusing solely on their degradation potency can be misleading. Unlike traditional drugs, these structures operate through an event-driven and catalytic mechanism, making it quite difficult to predict dose-response relationships. Biological effects can persist long after the molecule's concentration in the blood has dropped, and higher doses do not always create a greater effect. Pharmacodynamic measurements such as maximum degradation capacity and degradation half-life are critical for understanding whether the biological target has been reached. However, when these measurements are evaluated alone, they carry the risk of creating a misleading picture in the drug candidate selection process.

In summary, the PROTAC field has now entered a new phase of maturity. Future advancements will rely less on efforts to increase the potency of the molecules and more on translational discipline and a holistic approach applied from the very beginning of the development process. Drug developers must carefully balance potential with factors such as developability, pharmacology, safety, and manufacturability. Failure to achieve intracellular exposure, molecular instability, or formulation challenges during manufacturing are the main obstacles that can lead to the failure of a high-potential drug. Solving all these technical requirements in the early stages is the most critical step that must be taken to deliver this innovative treatment method to patients.